Related Experiment Videos
Comparing antigenicity and immunogenicity of engineered gp120
Suganya Selvarajah1, Bridget Puffer, Ralph Pantophlet
1The Scripps Research Institute, Department of Immunology, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
Journal of Virology
|September 15, 2005
Summary
Engineered HIV envelope proteins (gp120) were tested in rabbits to improve broadly neutralizing antibody responses. Mutants showed altered antibody profiles, with one enhancing anti-V3 antibodies and another dampening responses to specific epitopes.
Area of Science:
- Immunology
- Virology
- Protein Engineering
Background:
- The HIV envelope glycoprotein gp120 is a key target for neutralizing antibodies.
- Engineering gp120 aims to enhance responses to conserved neutralizing epitopes, like that recognized by antibody b12.
- Understanding the relationship between antigenicity and immunogenicity of engineered gp120 variants is crucial for vaccine development.
Purpose of the Study:
- To investigate the immune response in rabbits immunized with two engineered gp120 mutants.
- To explore how modifications to gp120 affect antibody recognition and neutralization breadth.
- To assess the potential of engineered gp120 to direct immune responses towards specific epitopes.
Main Methods:
- Two engineered gp120 mutants, GDMR and mCHO, were created and characterized.
- Rabbits were immunized with the engineered gp120 mutants and wild-type gp120.
- Serum mapping and neutralization assays were performed to analyze antibody responses.
Main Results:
- Both engineered gp120 mutants successfully dampened responses to targeted epitopes.
- The GDMR mutant elicited enhanced anti-V3 antibodies, improving neutralization of some primary viruses but losing neutralization of T-cell line adapted (TCLA) viruses.
- The mCHO mutant showed reduced neutralization of primary viruses, indicating epitope masking without eliciting b12-like antibodies.
Conclusions:
- Antibody responses to multiple gp120 epitopes can be modulated through protein engineering.
- Achieving precise focusing of immune responses to desired neutralizing epitopes requires iterative design and testing.
- These findings contribute to strategies for developing effective HIV vaccines by guiding antigen design.